

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173759 A2

(51) International Patent Classification:
C12N 15/85 (2006.01) A61K 31/711 (2006.01)

(21) International Application Number:
PCT/US2024/016097

(22) International Filing Date:
16 February 2024 (16.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/485,845 17 February 2023 (17.02.2023) US
63/587,718 03 October 2023 (03.10.2023) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: ZHAO, Hien, Thuy; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US). FREIER, Susan, M.; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US). WAN, W., Brad; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US). THOMAS, Antony; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US). MIGAWA, Michael, T.; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US). SETH, Punit, P.; 6773 Mallee St., Carlsbad, CA 92011 (US). FITZSIMMONS, Bethany; c/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(74) Agent: HEMMENDINGER, Lisa, M. et al.; Banner & Witcoff, Ltd., 1100 13th Street, N.W., Suite 1200, Washington, District of Columbia 20005-4051 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2024/173759 A2

(54) Title: COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSION

(57) Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in certain instances reducing the amount of alpha-synuclein protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of a synucleinopathy. Such synucleinopathies include Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multiple system atrophy (MSA), neuronopathic Gaucher's disease, and Alzheimer's disease.